Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New automated insulin system tested in tiny trial

NCT ID NCT05299177

Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a system that automatically adjusts insulin delivery using a continuous glucose monitor, a smartphone app, and an insulin pump. It aimed to see if the system could help adults with type 1 diabetes spend more time with their blood sugar in a healthy range. Only one person took part, and the trial was stopped early, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
InControl automated insulin delivery system (smartphone app, continuous glucose monitor, and insulin pump)
What this could lead to
If successful, this could help people with type 1 diabetes manage their blood sugar more easily with less effort.
What could go wrong
This was a very small feasibility study with only 1 participant, so results may not apply to others. The trial was terminated early, so data is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1 person

The number who actually took part.

Started

Apr 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years of age or older * Type 1 diabetes confirmed on the basis of clinical features * Type 1 diabetes for greater than 1 year * On an intensified insulin regimen with multiple dose injection or insulin pump for \> 3 months * HbA1c \>7.5% (58mmol/mol) (or %TIR 3.9-10mmol/L \<52% for participants already using a continuous glucose sensor) Exclusion Criteria: * Total daily insulin dose greater than 100 units * Weight greater than 140kg * Pregnant or planning pregnancy * Have active malignancy or under investigation for malignancy * Severe visual impairment * Reduced manual dexterity * Use of any automated insulin delivery system * Unable to participate due to other factors, as assessed by the Chief Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Imperial College London, Imperial College Healthcare NHS Trust

    London, W2 1PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.